Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

BioMarin Pharmaceutical Inc. (BMRN) had Revenue of $2.85B for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$2.85B
Net Income	$426.86M
Cost of Goods Sold	$580.24M
Gross Profit	$2.27B
Operating Expenses	$2.37B
Operating Income	$484.21M
Non-Operating Income/Expense	$57.55M
Pre-Tax Income	$541.76M
Normalized Pre-Tax Income	$541.76M
Income after Taxes	$426.86M
Income from Continuous Operations	$426.86M
Consolidated Net Income/Loss	$426.86M
Normalized Income after Taxes	$426.86M
EBIT	$484.21M
EBITDA	$572.30M
Weighted-Average Shares Outstanding (Basic)	190.03M
Weighted-Average Shares Outstanding (Diluted)	196.71M
Earnings per Share (EPS) (Basic)	$2.25
Earnings per Share (EPS) (Diluted)	$2.21
Balance Sheet Financials
Current Assets	$3.23B
Property, Plant, and Equipment	$1.04B
Long-Term Assets	$3.76B
Total Assets	$6.99B
Current Liabilities	$606.99M
Long-Term Debt	$595.14M
Long-Term Liabilities	$723.96M
Total Liabilities	$1.33B
Common Equity	$5.66B
Tangible Shareholders Equity	$5.21B
Shareholders Equity	$5.66B
Common Shares Outstanding	190.76M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$572.84M
Cash Flow from Investing Activities	$136.49M
Cash Flow from Financial Activities	$-526.45M
Beginning Cash	$755.13M
End Cash	$942.84M
Increase/Decrease in Cash	$187.72M
Stock-Based Compensation	$201.57M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.33
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.10
Debt to Equity Ratio	0.11
Gross Margin	79.67%
Operating Margin	16.97%
EBIT Margin	16.97%
EBITDA Margin	20.05%
Pre-Tax Profit Margin	18.98%
Profit Margin	14.96%
Free Cash Flow	$497.42M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.41
Inventory Turnover	0.47
Receiveable Turnover	4.32
Days Sales in Receivables	84.48
Return on Equity	7.54%
Return on Tangible Equity	8.20%
Return on Assets	6.11%
Return on Investments	6.83%
Book Value Per Share	$29.66
Free Cash Flow per Share	$2.53
Operating Cash Flow per Share	$2.91

Data from Zacks Investment Research, Inc.